Michael Andrews
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Michael Andrews has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Zsuzsanna Kuklenyik
Clinical Chemistry Branch, Division of Laboratory Sciences, Centers for Disease Control and Prevention, Atlanta, USA
2 shared publications - Andrew N. Hoofnagle
Department of Laboratory Medicine & Pathology, University of Washington , Seattle, WA
1 shared publication - Anna A. Ivanova
Clinical Chemistry Branch, Division of Laboratory Sciences, Centers for Disease Control and Prevention , Atlanta, GA
1 shared publication Antony Lehtikoski
Clinical Chemistry Branch, Division of Laboratory Sciences, Centers for Disease Control and Prevention, Atlanta, USA
1 shared publicationAvi Z. Rosenberg
Affiliation Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, United States of America
1 shared publicationAyako McGregor
Affiliation Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, United States of America
1 shared publication
Latest Publications
- Open Access
- 27 February 2026
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 418 (9) , 2619-2639
Effect of HDL disk and LDL dimer presence on lipoprotein particle number determination and subclassification
High-density and low-density lipoproteins (HDL and LDL) are established analytical targets for diagnosis and risk stratification of numerous chronic diseases. This study investigates potential sources of bias in lipoprotein particle counting (HDL-P and LDL-P), focusing on the most atheroprotective small-HDL and most pro-atherogenic small-LDL. Plasma samples were fractionated using asymmetric-flow field-flow fractionation (AF4), coupled with hydrodynamic size measurement and comprehensive liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of each fraction. Concentration-size profiles were deconvoluted into 10 HDL and 8 LDL Gaussian subspecies. Molecular volume ratios were used to evaluate proposed particle models, providing evidence for the presence of s-HDL disk and s-LDL dimers, as sources of bias in calculated HDL-P and LDL-P when spherical particle geometry is assumed. Matching apoA1/HDL-P and apoB/LDL-P to consensus values enabled correction of mass diameters (k*d m ), with k≈1.2 for s-HDL disks, and k≈0.8 for s-LDL dimers. These corrections resulted in closer agreements of the calculated HDL-P and LDL-P values with those reported by nuclear magnetic resonance spectroscopy (n = 666). After corrections, average AF4-LC-MS/MS versus NMR differences decreased from 20 to 4.9% for HDL-P and from −47% to −5.7% for LDL-P; x-y correlations improved from 0.83 to 0.85 and 0.51 to 1.03, respectively; and both platforms showed a dominant presence of s-HDL and s-LDL subclasses. Overall, the results support standardization of clinical methodologies for lipoprotein subclass measurement around apoA1 and apoB, and harmonization of HDL and LDL subclass definitions based on composition and structural characteristics rather than strictly enforced size cutoffs. Graphical abstract
- 27 February 2026
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 418 (9) , 2619-2639
Open AccessEffect of HDL disk and LDL dimer presence on lipoprotein particle number determination and subclassification
High-density and low-density lipoproteins (HDL and LDL) are established analytical targets for diagnosis and risk stratification of numerous chronic diseases. This study investigates potential sources of bias in lipoprotein particle counting (HDL-P and LDL-P), focusing on the most atheroprotective small-HDL and most pro-atherogenic small-LDL. Plasma samples were fractionated using asymmetric-flow field-flow fractionation (AF4), coupled with hydrodynamic size measurement and comprehensive liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of each fraction. Concentration-size profiles were deconvoluted into 10 HDL and 8 LDL Gaussian subspecies. Molecular volume ratios were used to evaluate proposed particle models, providing evidence for the presence of s-HDL disk and s-LDL dimers, as sources of bias in calculated HDL-P and LDL-P when spherical particle geometry is assumed. Matching apoA1/HDL-P and apoB/LDL-P to consensus values enabled correction of mass diameters (k*d m ), with k≈1.2 for s-HDL disks, and k≈0.8 for s-LDL dimers. These corrections resulted in closer agreements of the calculated HDL-P and LDL-P values with those reported by nuclear magnetic resonance spectroscopy (n = 666). After corrections, average AF4-LC-MS/MS versus NMR differences decreased from 20 to 4.9% for HDL-P and from −47% to −5.7% for LDL-P; x-y correlations improved from 0.83 to 0.85 and 0.51 to 1.03, respectively; and both platforms showed a dominant presence of s-HDL and s-LDL subclasses. Overall, the results support standardization of clinical methodologies for lipoprotein subclass measurement around apoA1 and apoB, and harmonization of HDL and LDL subclass definitions based on composition and structural characteristics rather than strictly enforced size cutoffs. Graphical abstract
- Open Access
- 24 October 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (10) , e0276649
Variant APOL1 protein in plasma associates with larger particles in humans and mouse models of kidney injury
Background: Genetic variants in apolipoprotein L1 (APOL1), a protein that protects humans from infection with African trypanosomes, explain a substantial proportion of the excess risk of chronic kidney disease affecting individuals with sub-Saharan ancestry. The mechanisms by which risk variants damage kidney cells remain incompletely understood. In preclinical models, APOL1 expressed in podocytes can lead to significant kidney injury. In humans, studies in kidney transplant suggest that the effects of APOL1 variants are predominantly driven by donor genotype. Less attention has been paid to a possible role for circulating APOL1 in kidney injury. Methods: Using liquid chromatography-tandem mass spectrometry, the concentrations of APOL1 were measured in plasma and urine from participants in the Seattle Kidney Study. Asymmetric flow field-flow fractionation was used to evaluate the size of APOL1-containing lipoprotein particles in plasma. Transgenic mice that express wild-type or risk variant APOL1 from an albumin promoter were treated to cause kidney injury and evaluated for renal disease and pathology. Results: In human participants, urine concentrations of APOL1 were correlated with plasma concentrations and reduced kidney function. Risk variant APOL1 was enriched in larger particles. In mice, circulating risk variant APOL1-G1 promoted kidney damage and reduced podocyte density without renal expression of APOL1. Conclusions: These results suggest that plasma APOL1 is dynamic and contributes to the progression of kidney disease in humans, which may have implications for treatment of APOL1-associated kidney disease and for kidney transplantation.
- 24 October 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (10) , e0276649
Open AccessVariant APOL1 protein in plasma associates with larger particles in humans and mouse models of kidney injury
Background: Genetic variants in apolipoprotein L1 (APOL1), a protein that protects humans from infection with African trypanosomes, explain a substantial proportion of the excess risk of chronic kidney disease affecting individuals with sub-Saharan ancestry. The mechanisms by which risk variants damage kidney cells remain incompletely understood. In preclinical models, APOL1 expressed in podocytes can lead to significant kidney injury. In humans, studies in kidney transplant suggest that the effects of APOL1 variants are predominantly driven by donor genotype. Less attention has been paid to a possible role for circulating APOL1 in kidney injury. Methods: Using liquid chromatography-tandem mass spectrometry, the concentrations of APOL1 were measured in plasma and urine from participants in the Seattle Kidney Study. Asymmetric flow field-flow fractionation was used to evaluate the size of APOL1-containing lipoprotein particles in plasma. Transgenic mice that express wild-type or risk variant APOL1 from an albumin promoter were treated to cause kidney injury and evaluated for renal disease and pathology. Results: In human participants, urine concentrations of APOL1 were correlated with plasma concentrations and reduced kidney function. Risk variant APOL1 was enriched in larger particles. In mice, circulating risk variant APOL1-G1 promoted kidney damage and reduced podocyte density without renal expression of APOL1. Conclusions: These results suggest that plasma APOL1 is dynamic and contributes to the progression of kidney disease in humans, which may have implications for treatment of APOL1-associated kidney disease and for kidney transplantation.